Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Serapha Bio Announces Positive Interim Safety and Efficacy Data from the SERP-01 Investigator-Initiated Trial Presented at the ERS Alpha-1 Antitrypsin Conference 2026

GlobeNewswire

NEW YORK, Oct. 26, 2026 -- Serapha Bio, Inc. (Serapha), a clinical-stage genetic medicines company committed to transforming the treatment of alpha-1 antitrypsin deficiency (AATD), today announced early clinical data for YOLT-202 (SERP-01), an investigational one-time in vivo base editing therapy, from the ongoing investigator-initiated trial (IIT) evaluating its safety and efficacy in four participants with the PiZZ genotype. Simon Krooss, M.D., Ph.D. of Hannover Medical School presented the data at the European Respiratory Society Alpha-1 Antitrypsin Conference 2026, held on October 23-24 in Barcelona, Spain. The IIT is being conducted through a collaboration between Renji Hospital in Shanghai, China and Hannover Medical School in Germany.

  1. FinanceCID Holdco, Inc.Dot Ai Appoints Technology Industry Veteran Avi Cohen to Board of DirectorsCID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC) (“Dot Ai” or the “Company”), today announced the appointment of Avi Cohen to its Board of Directors. Cohen brings extensive experience leading technology companies through acquisitions, integration and expansion as Dot Ai enters its next phase of growth following the recent $65 million acquisition of its wholly owned subsidiary, Envoy Technologies.
  2. Man Group PLC : Form 8.3 - Gamma Communications PlcFORM 8.3
  3. FinanceMacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic CancerMacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
  4. HBT Financial, Inc. Announces Third Quarter 2026 Financial ResultsHBT Financial, Inc. Announces Third Quarter 2026 Financial Results
  5. Aerospace & defenseKraig Biocraft Laboratories Launches Performance Yarn Development Program and Ships Spider Silk to Yarn and Aerospace InnovatorKraig Labs (OTCQB:KBLB) launched a new high-performance spider silk yarns and also shipped spider silk samples to a tier-1 aerospace manufacturers supplier
  6. HealthcareForm 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 23 10 2026] - (CGWL)FORM 8.3